Gastrointestinal motility in patients with neuroendocrine tumors


Introduction: Diarrhea is the most common symptom in patients with intestinal neuroendocrine tumors (NET). Somatostatin analogues reduce stool frequency and may increase gastrointestinal transit time (GITT). Motility tracking system® MTS-1 (MTS) (Motilis, Switzerland) is a novel, safe, almost non-invasive and easy-to-perform method for description of gastrointestinal motility.

Aim(s): To compare gastrointestinal transit times and motility patterns in patients with carcinoid syndrome before and after treatment with Sandostatin® LAR with those of healthy individuals.

Materials and methods: For MTS, a small magnetic pill (6x15 mm) was ingested and a matrix of magnetic field sensors (4x4) tracked the position of the magnet defined by five coordinates (position: x, y, z, angle: θ, φ). Ten patients with carcinoid syndrome (six men, age 32-73 years, median 66) and positive octreotide scintigraphy were investigated for 6-7 hours after three hours fast. Results were compared to 10 healthy subjects. Patients were studied before and during treatment with Sandostatin┬« LAR (30 mg injections given twice with an interval of three weeks).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Gregersen T

Authors: Gregersen T, Gronbaek H, Schlageter V, Fynne L, Worsoe J,

Keywords: neuroendocrine tumor, gastrointestinal motility,

To read the full abstract, please log into your ENETS Member account.